Selective D3 dopamine receptor agonists and methods of their use

US11634404B2 · kind B2 · utility

Assignees

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US
• University of Kansas · US
• The University of North Carolina at Chapel Hill · US

Inventors

• David R. Sibley · Gaithersburg, US
• Amy Elizabeth Moritz · Bethesda, US
• R. Benjamin Free · Bethesda, US
• Joseph P. Steiner · Hampstead, US
• Noel Terrence Southall · Bethesda, US
• Marc Ferrer · Potomac, US
• Xin Hu · Chestertown, US
• Warren S. Weiner · Salt Lake City, US
• Jeffrey Aube · Lawrence, US
• Kevin Frankowski · Lawrence, US

Key dates

• Filing date: Apr 14, 2017
• Grant date: Apr 25, 2023
• Expiry date: Nov 23, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The disclosure of a compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) The variables W, R1, R2, R3, and R4 are defined in the disclosure. The disclosure provides a compound or salt of Formula (I) together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula (I) is administered to the patient together with one or more additional active agents.